Neurocrine Biosciences develops treatments for rare and under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company offers FDA-approved therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis, and uterine fibroids. Neurocrine also maintains a pipeline of investigational compounds in mid-to-late phase clinical development, focusing on fulfilling unmet medical needs in these therapeutic areas. The company operates primarily in the United States and collaborates with other pharmaceutical companies for research and development initiatives.
No recent RNS announcements for 1NBIX across 1NBIX, NBIX.
No recent RNS announcements for 1NBIX across 1NBIX, NBIX.